PDF herunterladen
Exp Clin Endocrinol Diabetes 2018; 126(01): 53-60
DOI: 10.1055/s-0043-109242
Article
© Georg Thieme Verlag KG Stuttgart · New York

The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece

Emmanuel Pagkalos
1   Department of Diabetes, Clinic “Thermi”, Thessaloniki, Greece
,
Anastasia Thanopoulou
2   Second Department of Internal Medicine, General Hospital “Hippocratio”, National and Kapodistrian University, Athens, Greece
,
Christos Sampanis
3   Diabetes Centre, Second Propaedeutic Department of Internal Medicine “Hippocratio”, Thessaloniki, Greece
,
Stavros Bousboulas
4   Diabetes Centre, General Hospital “Ag. Panteleimon”, Piraeus, Greece
,
Andreas Melidonis
5   Diabetes Centre, General Hospital “Tzanio”, Piraeus, Greece
,
Nicholas Tentolouris
6   First Propaedeutic Department of Internal Medicine, General Hospital “Laiko”, National and Kapodistrian University, Athens, Greece
,
Theodoros Alexandrides
7   Department of Endocrinology, University General Hospital of Patras, Rion, Greece
,
Ilias Migdalis
8   Second Medical Department and Diabetes Centre, NIMTS Hospital, Greece
,
Eugenia Karamousouli
9   Merck Sharp & Dohme Pharmaceutical, Industrial and Commercial S.A, Athens, Greece
,
Nikolaos Papanas
10   Diabetes Centre, Second Department of Internal Medicine, University General Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 07. März 2017
revised 09. April 2017

accepted 19. April 2017

Publikationsdatum:
13. Juli 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Aim To investigate the prevalence of hypoglycaemia during sulfonylurea (SU) treatment of type 2 diabetes mellitus (T2DM) in Greece and its influence on glycaemic control, treatment adherence and quality of life (QoL).

Patients and methods This was a retrospective cross-sectional study. We included 383 T2DM patients ≥30 years old on treatment with SU in monotherapy or in combination with metformin for at least 6 months. Patients were requested to fill in retrospective questionnaires on hypoglycaemia experience, adherence, weight gain and lifestyle/behavioural factors along with QoL (EQ-5D-3L), treatment satisfaction (TSQM), and fear of hypoglycaemia (HFS-II Worry scale).

Results HbA1c<7% was found in 161 (42.0%) patients. In total, 165 (43.1%) patients reported hypoglycaemic symptoms during the previous 6 months: 41.6% (67/161) of those with HbA1c <7% and 44.1% (98/222) of those with HbA1c ≥7%. Glycaemic control was achieved by 43.1% (94/218) of patients without hypoglycaemia and 50.0% (41/82), 36.8% (25/68) and 6.7% (1/15) of patients with mild, moderate or severe hypoglycaemia, respectively (p=0.013). In multivariate analysis, both occurrence (none vs. mild/moderate/severe) and severity (none vs. mild vs. moderate vs. severe) of hypoglycaemia were significantly associated with impaired global treatment satisfaction (p=0.002 and p<0.0001 respectively) and HFS-II Worry scale scores (both p<0.0001), while lower QoL (EQ-5D (UK) Index) was related to hypoglycaemia severity (p=0.024) only. Finally, treatment adherence was associated with increased (none/mild vs. moderate/severe) hypoglycaemia severity in univariate analysis (p=0.019).

Conclusion A high prevalence of patient treated with SU reported hypoglycaemia in Greek healthcare settings with negative effects on treatment satisfaction, patient worry and adherence. Severity of hypoglycaemic symptoms was associated with reduced glycaemic control.

Key words

type 2 diabetes - sulfonylurea - hypoglycaemia - therapy outcome
 

  • References

  • 1 Cryer PE. Hypoglycaemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42-46
    CrossrefPubMedGoogle Scholar
  • 2 Barbosa J, Johnson S. Severe hypoglycaemia during maximized insulin treatment of diabetes in a randomized clinical trial. Diabetes Care 1983; 6: 62-63
    CrossrefPubMedGoogle Scholar
  • 3 Davis S, Alonso MD. Hypoglycaemia as a barrier to glycemic control. J Diabetes Complications 2004; 18: 60-68
    CrossrefPubMedGoogle Scholar
  • 4 Davis RE, Morrissey M, Peters JR. et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005; 21: 1477-1483
    CrossrefPubMedGoogle Scholar
  • 5 The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin – dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
    CrossrefPubMedGoogle Scholar
  • 6 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
    CrossrefPubMedGoogle Scholar
  • 7 ADVANCE Collaborative Group. Patel A, MacMahon S, Chalmers J. et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572
    CrossrefPubMedGoogle Scholar
  • 8 UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147
    CrossrefPubMedGoogle Scholar
  • 9 Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G. et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008; 10: 25-32
    CrossrefPubMedGoogle Scholar
  • 10 Vexiau P, Mavros P, Krishnarajah G. et al. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. Diabetes Obes Metab 2008; 10: 16-24
    PubMedGoogle Scholar
  • 11 Inzucchi SE, Bergenstal RM, Buse JB. et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
    CrossrefPubMedGoogle Scholar
  • 12 Inzucchi SE, Bergenstal RM, Buse JB. et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a Position Statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 2015; 38: 140-149
    CrossrefPubMedGoogle Scholar
  • 13 Koro CE, Bowlin SJ, Bourgeois N. et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care 2004; 27: 7-20
    PubMedGoogle Scholar
  • 14 Ali MK, Bullard KM, Saaddine JB. et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 2013; 368: 1613-1624
    CrossrefPubMedGoogle Scholar
  • 15 Sola D, Rossi L, Schianca GP. et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015; 11: 840-848
    PubMedGoogle Scholar
  • 16 Avramopoulos I, Moulis A, Nikas N. Glycaemic control, treatment satisfaction and quality of life in type 2 diabetes patients in Greece: The PANORAMA study Greek results. World J Diabetes 2015; 6: 208-216
    CrossrefPubMedGoogle Scholar
  • 17 Liatis S, Dafoulas GE, Kani C. et al. The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database. Diabetes Res Clin Pract 2016; 118: 162-167
    CrossrefPubMedGoogle Scholar
  • 18 Grant RW, Devita NG, Singer DE. et al. Improving adherence and reducing medication discrepancies in patients with diabetes. Ann Pharmacother 2003; 37: 962-969
    CrossrefPubMedGoogle Scholar
  • 19 The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208
    CrossrefPubMedGoogle Scholar
  • 20 Atkinson MJ, Sinha A, Hass SL. et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004; 2: 12
    CrossrefPubMedGoogle Scholar
  • 21 Cox DJ, Irvine A, Gonder-Frederick L. et al. Fear of hypoglycaemia: quantification, validation, and utilization. Diabetes Care 1987; 10: 617-621
    CrossrefPubMedGoogle Scholar
  • 22 Malouf R, Brust JC. Hypoglycemia: Causes, neurological manifestations, and outcome. Ann Neurol 1985; 17: 421-430
    CrossrefPubMedGoogle Scholar
  • 23 Dormandy JA, Charbonnel B, Eckland DJ. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289
    CrossrefPubMedGoogle Scholar
  • 24 Chan SP, Ji LN, Nitiyanant W. et al. Hypoglycemic symptoms in patients with type 2 diabetes in Asia-Pacific-Real-life effectiveness and care patterns of diabetes management: the RECAP-DM study. Diabetes Res Clin Pract 2010; 89: e30-e32
    CrossrefPubMedGoogle Scholar
  • 25 Miller CD, Phillips LS, Ziemer DC. et al. Hypoglycaemia in patients with type 2 diabetes mellitus. Arch Intern Med 2001; 161: 1653-1659
    CrossrefPubMedGoogle Scholar
  • 26 Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2010; 91: 363-370
    PubMedGoogle Scholar
  • 27 Lundkvist J, Berne C, Bolinder B. et al. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005; 6: 197-202
    CrossrefPubMedGoogle Scholar
  • 28 Marrett E, Radican L, Davies MJ. et al. Assessment of severity and frequency of selfreported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study. BMC Res Notes 2011; 4: 251
    CrossrefPubMedGoogle Scholar
  • 29 Leporini C, Piro R, Ursini F. et al. Monitoring safety and use of old and new treatment options for type 2 diabetic patients: A two-year (2013-2016) analysis. Expert Opin Drug Saf 2017; 15: 17-34
    PubMedGoogle Scholar
  • 30 Farmer AJ, Lonergan M, Rodger LR. et al. Adherence to oral glucose-lowering therapies and associations with 1-year HbA1c: A retrospective cohort analysis in a large primary care database. Diabetes Care 2016; 39: 258-263
    PubMedGoogle Scholar
  • 31 Sakamoto Y, Oyama J, Ikeda H. et al. Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol 2013; 12: 35
    CrossrefPubMedGoogle Scholar
  • 32 Mearns ES, Sobieraj DM, White CM. et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis. PLoS One 2015; 10: e0125879
    CrossrefPubMedGoogle Scholar
  • 33 Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015; 109: 378-388
    CrossrefPubMedGoogle Scholar
  • 34 Zhou JB, Bai L, Wang Y. et al The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: Accumulated evidence from randomised controlled trial. Int J Clin Pract 2016; 70: 132-141
    CrossrefPubMedGoogle Scholar